Uncategorized

Innate Pharma Highlights Clinical Abstracts Selected for ASCO 2023 Annual Meeting

Innate Pharma SA announced three abstracts including Innate’s product candidates have been accepted for the American Society for Clinical Oncology 2023 Annual Meeting, taking place June 2-6, 2023 in Chicago, IL. One abstract for SAR’579, currently developed by Sanofi, has been selected for oral presentation.

Innate Pharma Highlights Clinical Abstracts Selected for ASCO 2023 Annual Meeting Read More »

Sensorion Provides Preliminary Documents for the Combined Shareholders’ General Meeting of May 24, 2023

Sensorion announces that the Company’s shareholders are invited to participate in the Combined General Meeting, to be held on Wednesday, May 24, 2023, at 2 pm CET in the premises of the hotel Square Louvois, located at 12, rue de Louvois, 75002, Paris, France.

Sensorion Provides Preliminary Documents for the Combined Shareholders’ General Meeting of May 24, 2023 Read More »

IRLAB Comments on Statements in Ipsen’s 2022 Universal Registration Document and the Further Development of Mesdopetam

IRLAB Therapeutics AB announced that IRLAB has been made aware that Ipsen’s 2022 Universal Registration Document, published on April 6, 2023, contains incorrect information that the development and commercialization rights for mesdopetam have been transferred back to IRLAB.

IRLAB Comments on Statements in Ipsen’s 2022 Universal Registration Document and the Further Development of Mesdopetam Read More »

Lannett Company, Inc. Files Prepackaged Chapter 11 Cases to Significantly Strengthen Financial Position

Lannett Company, Inc. announced that it and certain of its subsidiaries have commenced prepackaged Chapter 11 cases in the United States Bankruptcy Court for the District of Delaware to effectuate the transactions contemplated by the Restructuring Support Agreement announced on May 1, 2023.

Lannett Company, Inc. Files Prepackaged Chapter 11 Cases to Significantly Strengthen Financial Position Read More »

Scroll to Top